These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 23952588

  • 1. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
    Hashim HZ, Norlinah MI, Nafisah WY, Tan HJ, Raymond AA, Tamil AM.
    Int J Neurosci; 2014 Mar; 124(3):187-91. PubMed ID: 23952588
    [Abstract] [Full Text] [Related]

  • 2. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators.
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [Abstract] [Full Text] [Related]

  • 3. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH, Tang BS, Song CY, Xu Q, Lou MX, Liu ZH, Yu RH, Yan XX, Guo JF.
    Neurosci Lett; 2013 Nov 27; 556():109-12. PubMed ID: 24135335
    [Abstract] [Full Text] [Related]

  • 4. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL, 228 Study Investigators.
    Mov Disord; 2010 May 15; 25(7):858-66. PubMed ID: 20461803
    [Abstract] [Full Text] [Related]

  • 5. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A, Mostile G, Nicoletti G, Arabia G, Iliceto G, Lamberti P, Marconi R, Morgante L, Barone P, Quattrone A, Zappia M.
    J Neurol; 2016 May 15; 263(5):888-894. PubMed ID: 26964541
    [Abstract] [Full Text] [Related]

  • 6. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E.
    Clin Neurol Neurosurg; 2006 Dec 15; 108(8):726-32. PubMed ID: 16564615
    [Abstract] [Full Text] [Related]

  • 7. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S, Pradhan R, Paul P, Das M, Gupta A, Ghosh P, Chatterjee S.
    Neurol Res; 2014 Sep 15; 36(9):841-6. PubMed ID: 24601722
    [Abstract] [Full Text] [Related]

  • 8. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug 15; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 9. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
    Kipfer S, Stephan MA, Schüpbach WM, Ballinari P, Kaelin-Lang A.
    Arch Neurol; 2011 Aug 15; 68(8):1037-9. PubMed ID: 21825240
    [Abstract] [Full Text] [Related]

  • 10. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE.
    N Engl J Med; 2000 May 18; 342(20):1484-91. PubMed ID: 10816186
    [Abstract] [Full Text] [Related]

  • 11. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A.
    Parkinsonism Relat Disord; 2005 May 18; 11(3):151-5. PubMed ID: 15823479
    [Abstract] [Full Text] [Related]

  • 12. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
    Liu G, Chen H, Su D, Wang D, Zhang M, Wang X, Wang Z, Yang Y, Jiang Y, Ma H, Feng T.
    Neurol Sci; 2020 Jan 18; 41(1):111-118. PubMed ID: 31446577
    [Abstract] [Full Text] [Related]

  • 13. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I.
    Parkinsonism Relat Disord; 2006 Dec 18; 12(8):499-505. PubMed ID: 16935018
    [Abstract] [Full Text] [Related]

  • 14. [Incidence and determinants of levodopa-induced dyskinesia in a retrospective cohort of Mexican patients with Parkinson's disease].
    Cervantes-Arriaga A, Rodríguez-Violante M, Salmerón-Mercado M, Calleja-Castillo J, Corona T, Yescas P, Alonso-Vilatela E.
    Rev Invest Clin; 2012 Dec 18; 64(3):220-6. PubMed ID: 23045943
    [Abstract] [Full Text] [Related]

  • 15. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.
    Mov Disord; 2013 Nov 18; 28(13):1838-46. PubMed ID: 23853029
    [Abstract] [Full Text] [Related]

  • 16. [Motor levodopa-induced complications in Parkinson's disease].
    Michałowska M, Fiszer U, Szatanowski T.
    Pol Merkur Lekarski; 2016 Jun 18; 40(240):357-61. PubMed ID: 27403901
    [Abstract] [Full Text] [Related]

  • 17. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 18; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 18. Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
    Kelly MJ, Lawton MA, Baig F, Ruffmann C, Barber TR, Lo C, Klein JC, Ben-Shlomo Y, Hu MT.
    Mov Disord; 2019 Aug 18; 34(8):1174-1183. PubMed ID: 31283854
    [Abstract] [Full Text] [Related]

  • 19. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE.
    Mov Disord; 2005 Mar 18; 20(3):342-4. PubMed ID: 15580606
    [Abstract] [Full Text] [Related]

  • 20. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA, Horstink MW, Zijlmans JC, Lemmens WA, Bloem BR, Borm GF.
    J Parkinsons Dis; 2015 Mar 18; 5(4):847-53. PubMed ID: 26444087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.